Catto JWF, Daneshmand S, Zaucha R, Tran B, Master V, Lotan Y, Pignot G, Tubaro A, Shimizu N, Vasdev N, Lee EK, Procopio G, Galanternik F, Fischer DS, Levin TG, Zhang J, Thomas S, Stone N, Triantos S, Beeharry N. A0591 Longitudinal assessment of urine tumor DNA in high-risk non-muscle invasive bladder cancer patients. European Urology. 2026;89:10.1016/s0302-2838(26)00642-1
Harris W, Shirley S, Liow E, Tan A, Jacobs C, Fong P, Fu S, Tan E, Waldron N, Weickhardt A, Wong S, Tran B, Lawrence N. Real-World Outcomes in Advanced Clear Cell Renal Cell Carcinoma: A Retrospective Analysis Comparing New Zealand and Australian Cohorts. JCO Global Oncology. 2026;12(3):10.1200/go-25-00384
Anton A, Steer C, Arasaratnam M, Torres J, Weickhardt A, Warren M, Mislang ARA, Azad AA, Linton A, Smith A, Rai S, Hong W, Gibbs P, Tran B. Registry-based randomised phase II study of Enzalutamide versus Abiraterone: assessing cognitive function in eLderly patients with metastatic castration-resistant Prostate cancer (REAL-Pro). ESMO Real World Data and Digital Oncology. 2026;11:10.1016/j.esmorw.2025.100677
Pan HY-C, Shi W, Mulholland C, Conduit C, Tran B, Hitchen N, Lawrentschuk N, Thomas B. Primary retroperitoneal lymph node dissection for clinical stage IIA/B metastatic seminoma: A multi-centre Australian experience.Journal of Clinical Oncology. 2026;44(7_suppl):10.1200/jco.2026.44.7_suppl.601
Conduit C, Sinn BV, Mitchell C, Leichsenring J, Laible M, Zlatic K, Kuba M, O’Haire S, Wöll S, Schlitter AM, Tran B. Evaluating Claudin-6 and isochromosome 12p in the progression from germ cell neoplasia in situ to primary testicular germ cell tumor and post-chemotherapy teratoma: implications for CLDN6-targeted therapies. Therapeutic Advances in Medical Oncology. 2026;18:10.1177/17588359261421810
Tran B, Lewin JH, O’Haire S, Grimison PS, Lynam JF, Jones K, Heron OM, Kuchel A, Campbell DC, Tung I, Marx GM, Namdarian B, Kuba M, Hitchen N, Nair A, Oakes SR, Hansen AR, Weickhardt AJ, Davis ID, Conduit C. Initial results from CLIMATE, a prospective cohort study assessing the clinical utility of miR-371a-3p (miR-371) as a marker of minimal residual disease (MRD) in clinical stage 1 testicular germ cell tumour (TGCT): ANZUP 1906.Journal of Clinical Oncology. 2026;44(7_suppl):10.1200/jco.2026.44.7_suppl.586
Mak B, Tran B, Thomas H, Walker R, Pashankar F, Feldman DR, Hansen AR, Huddart RA, Dunwoodie E, Wheater M, Stevanovic AG, Mazhar D, Lawrence NJ, Birtle AJ, Oladipo O, Wyld D, Balagtas JMS, Stockler MR, Grimison PS. P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for individuals aged 11-50 years with intermediate and poor-risk metastatic germ cell tumours (GCTs).Journal of Clinical Oncology. 2026;44(7_suppl):10.1200/jco.2026.44.7_suppl.tps623
Murtha AJ, Boni V, Loriot Y, Owens S, Lihou CF, Bernales CQ, Koudjanian M, Pham J, Goluboff ET, Degaonkar V, Burn T, Tran B, Vandekerkhove G, Wyatt AW. ctDNA monitoring of FGFR3-altered metastatic urothelial cancer treated with dabogratinib (formerly TYRA-300) in the SURF301 trial.Journal of Clinical Oncology. 2026;44(7_suppl):10.1200/jco.2026.44.7_suppl.809
Tran B, Dorff TB, Richey M, Hankinson E, Olsen P, Karwa S, Sharpe J, Braunlin M, Kim C. Treatment patterns and survival outcomes among lutetium 177–experienced patients with metastatic castration-resistant prostate cancer.Journal of Clinical Oncology. 2026;44(7_suppl):10.1200/jco.2026.44.7_suppl.69
De Bono JS, Fenor De La Maza MD, Boni V, Mateo J, Joshua AM, Eguren Santamaría I, Legrand FA, Pantoja C, Arum S, Da Silva DM, Kim S, Huynh C, Sager J, Wang V, Tran B. Preliminary phase 1 dose escalation results of VIR-5500 (AMX-500), a dual-masked PRO-XTEN T-cell engager, in metastatic castration resistant prostate cancer (mCRPC).Journal of Clinical Oncology. 2026;44(7_suppl):10.1200/jco.2026.44.7_suppl.17
